Prof Sagar Lonial talks to ecancer at the International Myeloma Workshop 2019 about iberdomide. Iberdomide is a novel cereblon E3 ligase modulator with enhanced tumoricidal and immunostimulatory activities.
It overcomes IMiD immunomodulatory drug resistance and has synergy with daratumumab, bortezomib, and dexamethasone.
Prof Lonial outlines some of the data from the trial focussing on the combination with dexamethosone, as well as toxicity profile.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
0 Comments